Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

Open access
Qiao, You-Lin, Wu, Ting, Li, Rong-Cheng, Hu, Yue-Mei, Wei, Li-Hui, Li, Chang-Gui, Chen, Wen, Huang, Shou-Jie, Zhao, Fang-Hui, Li, Ming-Qiang, Pan, Qin-Jing, Zhang, Xun, Li, Qing, Hong, Ying, Zhao, Chao, Zhang, Wen-Hua, Li, Yan-Ping, Chu, Kai, Li, Mei, Jiang, Yun-Fei, Li, Juan, Zhao, Hui, Lin, Zhi-Jie, Cui, Xue-Lian, Liu, Wen-Yu, Li, Cai-Hong, Guo, Dong-Ping, Ke, Li-Dong, Wu, Xin, Tang, Jie, Gao, Guo-Qi, Li, Ba-Yi, Zhao, Bin, Zheng, Feng-Xian, Dai, Cui-Hong, Guo, Meng, Zhao, Jun, Su, Ying-Ying, Wang, Jun-Zhi, Zhu, Feng-Cai, Li, Shao-Wei, Pan, Hui-Rong, Li, Yi-Min, Zhang, Jun, Xia, Ning-Shao · 2020 · JNCI: Journal of the National Cancer Institute

Abstract

Background: The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase III clinical trial was conducted to evaluate the efficacy, safety, and immunogenicity of a novel Escherichia coli-produced bivalent HPV-16/18 vaccine. Methods: A multicenter, randomized, double-blind trial started on November 22, 2012 in China. In total, 7372 eligible women aged 18–45 years were age-stratified and randomly assigned to receive three doses of the test or control (hepatitis E) vaccine at months 0, 1, and 6. Co-primary endpoints included high-grade genital lesions and persistent infection (over 6 months) associated with HPV-16/18. The primary analysis was performed on a per-protocol susceptible population of individuals who were negative for relevant HPV type-specific neutralizing antibodies (at day 0) and DNA (at day 0 through month 7) and who received three doses of the vaccine. This report presents data from a prespecified interim analysis used for regulatory submission. Results: In the per-protocol cohort, the efficacies against high-grade genital lesions and persistent infection were 100.0% (95% confidence interval = 55.6% to 100.0%, 0 of 3306 in the vaccine group vs 10 of 3296 in the control group) and 97.8% (95% confidence interval = 87.1% to 99.9%, 1 of 3240 vs 45 of 3246), respectively. The side effects were mild. No vaccine-related serious adverse events were noted. Robust antibody responses for both types were induced and persisted for at least 42 months. Conclusions: The E coli-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18–associated high-grade genital lesions and persistent infection in women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djz074

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
Qiao, Y.-L., Wu, T., Li, R.-C., Hu, Y.-M., Wei, L.-H., Li, C.-G., Chen, W., Huang, S.-J., Zhao, F.-H., Li, M.-Q., Pan, Q.-J., Zhang, X., Li, Q., Hong, Y., Zhao, C., Zhang, W.-H., Li, Y.-P., Chu, K., Li, M., Jiang, Y.-F., Li, J., Zhao, H., Lin, Z.-J., Cui, X.-L., Liu, W.-Y., Li, C.-H., Guo, D.-P., Ke, L.-D., Wu, X., Tang, J., Gao, G.-Q., Li, B.-Y., Zhao, B., Zheng, F.-X., Dai, C.-H., Guo, M., Zhao, J., Su, Y.-Y., Wang, J.-Z., Zhu, F.-C., Li, S.-W., Pan, H.-R., Li, Y.-M., Zhang, J., & Xia, N.-S.
Venue
JNCI: Journal of the National Cancer Institute
Published
2019-05-14
Volume
112
Issue
2
Pages
145-153
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2945441427
Cited by
170
References
4
FWCI
11.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. https://app.cochat.ai/papers/10.1093/jnci/djz074
The paper
Qiao, Y.-L., Wu, T., Li, R.-C., Hu, Y.-M., Wei, L.-H., Li, C.-G., Chen, W., Huang, S.-J., Zhao, F.-H., Li, M.-Q., Pan, Q.-J., Zhang, X., Li, Q., Hong, Y., Zhao, C., Zhang, W.-H., Li, Y.-P., Chu, K., Li, M., . . . Xia, N.-S. (2020). Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djz074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.